Back

Levosimendan versus dobutamine in cardiogenic shock. A real alternative?

3 March 2019 (09:00 - 17:30)
Organised by:
Congress Presentation Part of: Poster Session 2 - Acute Heart Failure: Pharmacotherapy Pharmacotherapy ACVC Premium Access Acute Cardiovascular Care 2019

About the speaker

Photo
Doctor Miguel Jose Corbi Pascual

University Hospital Complex of Albacete, Albacete (Spain)

3 More presentations in this session

Presentation thumbnail
Doctor Y. Suzuki (Nagakute-cho, JP)
Presentation thumbnail
Mr J. Lopes (Coimbra, PT)
Abstract Slides
Presentation thumbnail
Doctor M. Pires (Viseu, PT)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 2 - Acute Heart Failure: Pharmacotherapy

The Event

Event poster

Acute Cardiovascular Care 2019

3 March 2019 09:00 CET
You may be interested in
thumbnail
Congress Presentation
Experience with levosimendan in cardiogenic shock: inotrope weaning and clinical outcomes in a real-world cohort
21 March 2026
thumbnail
Congress Presentation
Meta-analysis comparing the efficacy of dobutamine versus milrinone in acute decompensated heart failure and cardiogenic shock.
27 August 2022
thumbnail
Congress Presentation
When the cause is not ischemic: cardiogenic shock due toTakotsubo syndrome versus acute coronary syndrome
21 March 2026
thumbnail
Congress Presentation
Low-dose dobutamine infusion and single-dose tocilizumab in acute myocardial infarction patients with high risk of cardiogenic shock development - rationale and design of the DOBERMANN trial
24 March 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources